Last reviewed 2026-04-23 · How we verify

IVM plus ALB

IVM (ivermectin) and ALB (albendazole) are antiparasitic agents that work synergistically to paralyze and kill parasitic worms by disrupting their neuromuscular function.

IVM (ivermectin) and ALB (albendazole) are antiparasitic agents that work synergistically to paralyze and kill parasitic worms by disrupting their neuromuscular function. Used for Helminthic infections (specific indication under investigation in phase 3 trial at University Hospitals Cleveland Medical Center).

At a glance

Mechanism of action

Ivermectin binds to glutamate-gated chloride channels in parasitic nematodes and arthropods, causing paralysis and death. Albendazole inhibits microtubule polymerization in parasites, disrupting their motility and nutrient absorption. The combination targets complementary mechanisms to enhance efficacy against helminthic infections.

Approved indications

• Helminthic infections (specific indication under investigation in phase 3 trial at University Hospitals Cleveland Medical Center)

Common side effects

• Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
• Headache
• Dizziness
• Pruritus
• Elevated liver enzymes

Key clinical trials

• Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
• Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness (PHASE3)
• Co-administration of IVM and ALB in School-based Deworming in Uganda
• Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration (PHASE2, PHASE3)
• Embryo Developmental Potential in a Novel 2-step IVM System (NA)
• Safety and Efficacy of IDA for Onchocerciasis (PHASE2)
• Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura (PHASE3)
• Efficacy and Safety of IVM/ALB Co-administration (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.